Prospective observational study on metabolic changes induced by SGLT2 inhibitors or insulin treatment in a single-center, two-arm, open-label design - prospective observational study on metabolic changes induced by SGLT2 inhibitors or insulin treatment

The intervention did not induce significant differences in HbA1c between the groups. The dapagliflozin group showed a significant decrease in body fat mass and percentage, along with an increase in skeletal muscle percentage. Among analyzed the 10 urinary biomarkers of diabetic kidney disease, only 3OH propionic acid showed a significant increase in the dapagliflozin-treated group compared to the insulin-treated group, suggesting that dapagliflozin modulates BCAA metabolism primarily in the kidney.